Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission

NCT02428543 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.

NCT NCT02428543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02428543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission
Lead sponsor
Versailles Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2013
Completion date
October 3, 2023
Enrollment
49 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid lukemia